Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 25, 2021

Humanigen gains BARDA access to produce lenzilumab for treating Covid-19

Humanigen has announced an expansion to the Cooperative Research and Development Agreement (CRADA) with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

Humanigen secures manufacturing capacity reserved by BARDA. (Credit: Pixabay/Gerd Altmann.)